Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC
Clinical trial NCT06059885 · UNKNOWN
Trial details
- NCT number
- NCT06059885
- Sponsor
- Beijing 302 Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-22
- Primary completion
- 2025-03-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.